Results 161 to 170 of about 6,725 (211)

Evaluating the Effectiveness of Large Language Models in Providing Patient Education for Chinese Patients With Ocular Myasthenia Gravis: Mixed Methods Study. [PDF]

J Med Internet Res
Wei B, Yao L, Hu X, Hu Y, Rao J, Ji Y, Dong Z, Duan Y, Wu X.   +8 more
europepmc   +1 more source

Juvenile ocular myasthenia gravis: a report of two cases. [PDF]

Digit J Ophthalmol
Gabbard R, Yi R, Pratt J, Chang K, Keck K.   +4 more
europepmc   +1 more source

Ocular Myasthenia Gravis As Unilateral Ptosis and External Ophthalmoplegia: A Case Report. [PDF]

Cureus
Tanveer S, Tahir A, Ahmad O, Bibi K, Khan S.   +4 more
europepmc   +1 more source

Efgartigimod-associated Kaposi's varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review. [PDF]

Front Immunol
Ge L, Li Y, Sun Y, Chen W, Ni X, Wei F, Mu Z.   +6 more
europepmc   +1 more source

Peribulbar Corticosteroids for Ocular Myasthenia Gravis [PDF]

Journal of Neuro-Ophthalmology
Background: Ocular myasthenia gravis is treated predominantly by oral medications, with the potential for systemic adverse effects. Successful treatment has been achieved using peribulbar dexamethasone. We assessed the effect of peribulbar dexamethasone or triamcinolone (40-mg Triesence), a longer-acting corticosteroid ...
Rachel Lasry, Marc Gotkine, Joshua M. Kruger   +2 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Ocular myasthenia gravis

Current Treatment Options in Neurology, 2001
Treatment decisions for ocular myasthenia gravis (OMG) should be based on symptomatology. Local, nonpharmacologic treatment of ptosis or diplopia is successful in relatively few patients, and the majority of patients require drug therapy for satisfactory resolution of their symptoms.
Victoria S., Pelak, Steven L., Galetta
openaire   +2 more sources

Ocular myasthenia gravis

Current Opinion in Ophthalmology, 2012
To review ocular myasthenia gravis (OMG), a localized form of myasthenia gravis clinically involving only the extraocular, levator palpebrae superioris, and orbicularis oculi muscles.Ocular manifestations can masquerade as a variety of ocular motility disorders, including central nervous system disorders and peripheral cranial nerve palsies.
Michael S, Vaphiades, M Tariq, Bhatti, Robert L, Lesser   +2 more
openaire   +2 more sources

Ocular myasthenia gravis

Russian Annals of Ophthalmology
Myasthenia gravis is an autoimmune disease characterized by muscle weakness and pathological fatigue due to autoaggressive phenomena with the formation of antibodies directed against various structures of the neuromuscular synapse. In most patients, the disease begins with the involvement of extraocular muscles, presenting with symptoms such as ...
M.S. Sergeeva, S.S. Danilov, N.I. Sherbakova   +2 more
openaire   +3 more sources

Ocular Aspects of Myasthenia Gravis

Seminars in Neurology, 2000
Ocular myasthenia gravis is a not uncommon autoimmune disorder causing diplopia, ptosis, and weakness of lid closure. The predilection of myasthenia for the ocular muscles may be related to differences between limb and extraocular muscles in either physiological function or antigenicity. Clinically, ocular myasthenia can mimic any form of pupil-sparing
J J, Barton, M, Fouladvand
openaire   +2 more sources

Update on Ocular Myasthenia Gravis

Neurologic Clinics, 2017
Ocular myasthenia gravis (OMG) is a localized form of myasthenia gravis in which autoantibodies directed against acetylcholine receptors block or destroy these receptors at the postsynaptic neuromuscular junction. The hallmark of OMG is a history of painless weakness or fatigability of the extraocular muscles and ptosis with normal pupillary function ...
Stacy V, Smith, Andrew G, Lee
openaire   +2 more sources